Hyperlipidemia: a new therapeutic target for diabetic neuropathy by Vincent, Andrea M. et al.
Journal of the Peripheral Nervous System 14:257–267 (2009)
2009 PNS PLENARY LECTURE AND REVIEW
Hyperlipidemia: a new therapeutic target for diabetic
neuropathy
Andrea M. Vincent1, Lucy M. Hinder1, Rodica Pop-Busui2, and Eva L. Feldman1
1Department of Neurology; and 2Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
Abstract Emerging data establish dyslipidemia as a significant contributor to the
development of diabetic neuropathy. In this review, we discuss how separate metabolic
imbalances, including hyperglycemia and hyperlipidemia, converge on mechanisms leading
to oxidative stress in dorsal root ganglia (DRG) sensory neurons. We conclude with
suggestions for novel therapeutic strategies to prevent or reverse diabetes-induced nerve
degeneration.
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Significance of the Problem
Diabetes mellitus affects over 20 million people in
the United States and a number of diabetic patients
are increasing by 5% per year (www.diabetes.org).
The most common complication of diabetes is diabetic
neuropathy. Depending on the diagnostic criteria used,
at least 50% up to 90% of individuals with diabetes will
develop diabetic neuropathy. The most common form
of diabetic neuropathy is diabetic polyneuropathy, a
symmetric loss of nerve function beginning in the toes
and progressing in a distal to proximal fashion, yielding
what is commonly called a stocking/glove pattern of
sensory loss (Edwards et al., 2008). While all sensory
modalities are eventually affected, recent studies show
that initially small unmyelinated and thinly myelinated
fibers are injured and, especially early in the disease,
patients can present with pain. Twenty-five years after
the diagnosis of diabetes, the cumulative risk of a
lower extremity amputation is 22% and, in the general
population, 60% of all lower extremity amputations
are secondary to diabetic neuropathy. This represents
a cost of over $22 billion per year and a significant
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loss of quality of life for diabetic patients (Barrett et al.,
2007). Although therapies are available to alleviate
the symptoms of diabetic neuropathy, these rarely
impact upon the root causes of the disease (Feldman
et al., 2002). The immense physical, psychological, and
economic cost of diabetic neuropathy underscores
the need for causally targeted therapies (Kles and
Vinik, 2006).
Oxidative Stress in Diabetes
There is a growing consensus, driven by both clin-
ical and basic studies, that oxidative stress underlies
the development of the microvascular complications
of diabetes, including diabetic neuropathy (Low et al.,
1997; Ziegler et al., 2004; Russell et al., 2008; Vincent
et al., 2008). In type 1 diabetic patients, the severity
of microvascular complications parallels the degree of
systemic oxidative stress (Sullivan and Feldman, 2005;
Giugliano et al., 2008). With disease and diabetic neu-
ropathy progression, antioxidant potential decreases
while lipid peroxidation products increase. Type 2 dia-
betic patients have a similar oxidative stress profile
which directly relates the onset and progression of
microvascular complications (Greene et al., 1999; Vin-
cent et al., 2004b).
In the late 1990s, our group introduced the idea
that glucose-mediated oxidative stress injures the
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peripheral nervous system, leading to eventual death
and loss of neurons and supporting Schwann cells
(Feldman et al., 1997; Russell et al., 1998; 1999; 2001).
Investigation of the basic mechanisms underlying
this process in DRG neurons identified multiple
mechanisms by which hyperglycemia mediates
DRG neuron injury. Mitochondrial overload is the
principal site of reactive oxygen species (ROS)
generation in hyperglycemia (Vincent et al., 2005a).
DRG neurons may be preserved in vitro in the face of
hyperglycemic insult by uncoupling agents that relieve
the mitochondrial overload (Vincent et al., 2004a) and
by lipophilic antioxidants that protect the mitochondria
against ROS injury (Vincent et al., 2005a; 2005b).
Additional cellular mechanisms are activated
by hyperglycemia to produce ROS. Hyperglycemia
leads to the formation of advanced glycation end
products (AGE). DRG neurons express the receptor
for AGE and exposure to AGE leads to oxidative
stress and injury in DRG neurons that is partially
mediated through activation of the nicotinamide
adenine dinucleotide phosphate [NAD(P)H] oxidase
complex (Vincent et al., 2007a). In addition, direct
exposure to hyperglycemia leads to the activation of
NAD(P)H oxidase (Vincent et al., 2005a). This complex
is formed through recruitment of a combination
of a p22-phox subunit and five NOX subunits
(Baumer et al., 2008). Within neurons, NOX2 (or
gp91-phox) and p22-phox are expressed within the
cell membrane; p47-phox and p67-phox are recruited
from the cytoplasm to the membrane when the
neuron is exposed to an NAD(P)H oxidase activating
stimulus (Murdoch et al., 2006). NAD(P)H oxidase
activity generates superoxide (O .−2 ) that promotes
mitochondrial dysfunction and apoptosis in the
setting of inflammation, neurodegeneration and in
atherosclerosis (Stamler, 1996; Silver et al., 2007).
Over time, these mechanisms act in concert with
accumulating ROS-induced damage that impairs nerve
function and results in the signs and symptoms
of diabetic neuropathy (Feldman et al., 1997; 2002;
Greene et al., 1999; Vincent and Feldman, 2004;
Vincent et al., 2004b; 2007b).
Pathophysiology of Diabetic
Neuropathy: More Than Just Glucose
Until recently, we (Feldman et al., 1997; 2002;
Greene et al., 1999; Vincent et al., 2004b) and other
investigators (Low et al., 1997; Brownlee, 2005;
Osawa and Kato, 2005; Tomlinson and Gardiner,
2008) in the field contended that hyperglycemia
was the driving force underlying the development
of diabetic neuropathy. Our opinions were based
originally on results from The Diabetes Control and
Complications Trial (DCCT). In the DCCT, type 1
diabetic subjects receiving intensive therapy with
an average glycosylated hemoglobin (HbA1c) of
7.2% had a reduced 60% cumulative incidence
of diabetic neuropathy when compared to patients
receiving conventional treatment (average HbA1c of
9.0%) (The Diabetes Control and Complications Trial
Research Group, 1993). However, the continuing
longitudinal study of the DCCT, the Epidemiology
of Diabetes Complications and Interventions Cohort
(EDIC) yielded unanticipated results 20 years later
(Genuth, 2006; Martin et al., 2006; Pop-Busui et al.,
2009). Within 1 year of discontinuing the DCCT and
beginning EDIC, the glycemic control in the two
treatment groups equalized to an average HbA1c
of 8% (Genuth, 2006). All 1,300 patients were
examined annually for diabetic neuropathy; one decade
later, patients from the intensive-DCCT cohort had
a lower incidence of diabetic neuropathy compared
to patients from the conventional-DCCT cohort,
despite 10 years of convergent glycemic control
(Martin et al., 2006). The underlying mechanism(s)
of this result is not determined, but one interesting
difference is the lipid profiles of the two groups:
a subset of the intensive-DCCT cohort has less
dyslipidemia than the conventional cohort (Diabetes
Control and Complications Trial Cohort, 1999; Lyons
et al., 2004). This interesting, unanticipated finding is
further supported by the Eurodiab Trial, a longitudinal
study of over 3,000 individuals with type 1 diabetes
(Tesfaye et al., 2005; Tesfaye, 2007). Of the 1,200
subjects who did not have diabetic neuropathy at
baseline, hypertension, serum lipids and body mass
index were each independently associated with
the risk of developing diabetic neuropathy during
a 7-year follow-up period. Of these risk factors,
dyslipidemia was closely linked with the onset
and progression of diabetic neuropathy [reviewed
in (Leiter, 2005)]. In support of these findings, we
recently evaluated the mechanisms underlying diabetic
neuropathy progression using indexes of sural nerve
morphometry obtained from two identical randomized,
placebo-controlled clinical trials (Wiggin et al., 2009).
Sural nerve myelinated fiber density, nerve conduction
velocities, vibration perception thresholds, clinical
symptom scores, and a visual analog scale for pain
were analyzed in participants with mild-to-moderate
diabetic neuropathy. A loss of ≥500 fibers/mm2 in
sural nerve myelinated fiber density over 52 weeks
was defined as progressing diabetic neuropathy, and
a myelinated fiber density loss of ≤100 fibers/mm2
during the same time interval as nonprogressing
diabetic neuropathy. In this cohort of participants,
elevated triglycerides were the only clinical parameter
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Figure 1. Myelinated fiber density (MFD) of the rapidly progressing and nonprogressing diabetic patients. (A) The
nonprogressing dataset shows no change in MFD (fibers/mm2) over 52 weeks, while the progressing dataset shows a
highly significant decrease in MFD. Baseline measurements of triglyceride levels (B) and peroneal motor nerve conduction
velocity (C) are significantly different between the progressing and nonprogressing participants. *p < 0.05; **p < 0.01;
***p < 0.0001 (reproduced from Wiggin et al., 2009).
that correlated with a loss of myelinated fiber density,
independent of disease duration, age, diabetes control,
or other variables (Wiggin et al., 2009). The nerve fiber
densities, triglycerides, and motor nerve conduction
velocities for the two groups are presented in Fig. 1.
Dyslipidemia and Neuropathy: An
Expanding Problem
The emerging idea that dyslipidemia contributes
to the development of diabetic neuropathy may
explain the earlier incidence of diabetic neuropathy
in individuals with type 2 compared to type 1 diabetes.
Lipid profiles are commonly abnormal early in the
course of type 2 diabetes in a temporal pattern that
correlates with the presence of diabetic neuropathy
[Diabetes Atorvastin Lipid Intervention (DALI) Study
Group, 2001; Clemens et al., 2004]. In contrast, lipid
profiles are nearly always normal in type 1 patients
at the time of diabetes diagnosis (Leiter, 2005).
Dyslipidemia develops later in the course of type 1
diabetes, and these abnormal lipid profiles coincide
with the delayed onset and progression of diabetic
neuropathy (Young et al., 1993; Kempler et al., 2002).
Accumulating data from several large scale trials of
patients with type 2 diabetes also point to early
dyslipidemia as a major independent risk factor for
the development of diabetic neuropathy [reviewed
in (Cameron et al., 2003; Leiter, 2005; Gordon and
Robinson, 2006)]. In the United Kingdom Prospective
Diabetes Study (UKPDS), 3,867 newly diagnosed type
2 patients were randomized into either intensive
treatment with an oral hypoglycemic agent or insulin
or conventional treatment with diet. After 10 years,
intensive treatment resulted in approximately 1%
lower HbA1c vs. conventional treatment but there
was no difference in the development of diabetic
neuropathy between the two groups, which had similar
lipid and blood pressure profiles [UK Prospective
Diabetes Study (UKPDS) Group, 1998]. This finding,
at first unexpected in light of the earlier DCCT data,
was supported by the VA Cooperative Study, which
demonstrated no difference in the prevalence of
diabetic neuropathy in type 2 diabetic patients over
a 2-year period comparing standard and intensive
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glycemic control (Azad et al., 1999). These results
suggested that independent factors other than
glycemic control are critical to the development of
diabetic neuropathy (Leiter, 2005).
As with EDIC and Eurodiab, analysis of the UKPDS
and VA cooperative data points to dyslipidemia as
a critical independent factor for the development of
diabetic neuropathy (Leiter, 2005). Type 2 diabetes
clusters with risk factors for coronary heart disease
including obesity, hypertension, and dyslipidemia;
individuals with two or more of these factors are
diagnosed with the metabolic syndrome (Fonseca,
2005; Grundy, 2005; Bonora, 2006; Zimmet and Alberti,
2008). In a cross-sectional study of 548 type 2 diabetic
subjects, those with metabolic syndrome were twice
as likely to have diabetic neuropathy (Isomaa et al.,
2001), and the driving factor was dyslipidemia. In a
European study of 85 type 2 diabetic patients with at
least two additional metabolic syndrome parameters,
the prevalence of microvascular complications,
including diabetic neuropathy, increased with each
additional parameter present (Isomaa et al., 2001);
abnormalities in (low-density lipoprotein) LDL profiles
were more closely related to diabetic neuropathy
than hyperglycemia. Finally, prospective studies of
patients with idiopathic neuropathy, including our own
recently published work, confirm a higher prevalence
of hyperlipidemia than impaired glucose tolerance
or hypertension, suggesting that dyslipidemia is an
essential factor underlying nerve injury (Gordon and
Robinson, 2006; Wiggin et al., 2009). Collectively, this
evolving and exciting literature links dyslipidemia to the
development and progression of diabetic neuropathy.
Fig. 2 outlines our current understanding of the
factors that contribute to the development of diabetic
neuropathy.
Lipid Modification in Diabetes
We have now employed cell culture and mouse
models of diabetic neuropathy and suggest that
oxLDLs are one notable ‘lipid factor’ responsible for
nervous system injury (Vincent et al., 2009). LDL is the
primary carrier of cholesterol (Hammer et al., 1995)
and vitamin E (Heinecke, 1987) within the plasma.
Systemic oxidative stress results in the modification
of these lipoproteins, which is well characterized in
atherosclerosis (Willems et al., 1998; Tsuzura et al.,
2004). LDLs spontaneously oxidize in the presence
of ROS such as superoxide (O .−2 ) to form oxLDLs
(Hammer et al., 1995). Cholesterol carrying LDLs is
more prone to oxidation than smaller, high-density
particles (Krentz, 2003).
oxLDLs are critically involved in endothelial cell
dysfunction, evident from the large body of literature
implicating oxLDLs in atherosclerotic lesion formation
(Li and Mehta, 2005; Ceriello, 2006; Genuth, 2006).
oxLDL is strongly cytotoxic, which may explain the
areas of necrosis detected within atherosclerotic
lesions (Tsuzura et al., 2004; Li and Mehta, 2005;
Pennathur and Heinecke, 2007; Thum and Borlak,
2008). In man, oxLDL is a highly analytic marker
for macrovascular disease, including stroke and
myocardial infarction (Tsimikas et al., 2005). In patients
with types 1 and 2 diabetes, serum levels of oxLDL
in proportion to total LDL particles are associated
with diabetic neuropathy (Willems et al., 1998; Tsuzura
et al., 2004). Fig. 3 illustrates our findings that oxLDLs
increase significantly in mice on a high-fat diet. These
oxLDLs can be found in the DRG and the mice develop
early signs and symptoms of diabetic neuropathy
















Figure 2. Hyperglycemia and hyperlipidemia contribute to the pathogenesis of diabetic neuropathy. Adapted from
Brownlee, 2005.
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Figure 3. Mice on a high-fat diet increase oxLDL and develop neuropathy. (A) Pooled plasma samples (2 pools/group, each
pool analyzed three times) were subjected to fractionation by FPLC, then cholesterol (A) was measured in each fraction. The
graph shows the mean and standard error of the mean for n = 2 pools/group. (B) Oxidative stress measures in the low-density
lipoprotein (LDL) fraction by reverse phase high performance liquid chromatography. HODE, dityrosine, and nitrotyrosine
were all significantly increased (p < 0.05). (C) Representative intraepidermal nerve fiber density images from one control and
one high-fat fed mouse footpad. Bar = 50 μm; d = dermis, e = epidermis. White dots indicate nerve fibers counted. (D) In a
different mouse study using obese db/db mice, we immunostained the dorsal root ganglia for ApoB and MDA-oxidized LDL.
We observed colocalization of MDA-LDL in green and ApoB in red (yielding a yellow signal) around the neurons (arrows) (A-C
reproduced from Vincent et al., 2009).
oxLDLs Mediate Cellular Injury via the
Scavenger Receptor, LOX-1
oxLDLs cause apoptotic injury and death in
both endothelial cells (Dimmeler et al., 1997) and
neurons (Papassotiropoulos et al., 1996; Draczynska-
Lusiak et al., 1998a; 1998b; Keller et al., 1999;
2000; Schroeter et al., 2000). In endothelial cells,
oxLDLs induce multiple events associated with apop-
totic injury, including Bid degradation, cytochrome c
release, and caspase-3 activation (Vindis et al., 2005).
oxLDLs are associated with increased proapoptotic
Bax and decreased levels of the anti-apoptotic type I
IGF receptor (IGF-IR) in smooth muscle cells (Higashi
et al., 2005). Both death receptor and mitochon-
drial pathways are involved in atherosclerotic-plaque
associated apoptosis induced by oxLDLs (Napoli,
2003). In neurons, oxLDLs induce DNA fragmen-
tation characteristic of apoptosis in DRG (Papas-
sotiropoulos et al., 1996; Vincent et al., 2009), striatal
neurons (Draczynska-Lusiak et al., 1998b; Schroeter
et al., 2000), and PC-12 cells (Draczynska-Lusiak et al.,
1998a). In motor neurons, oxLDLs increase ROS
and activate a caspase-3-dependent death mechanism
(Keller et al., 2000). Specific effects of oxLDL on mito-
chondria and mitochondrial-mediated apoptotic events
in neurons remain unknown.
oxLDLs exert effects on cells through two
primary cell surface receptors, lectin-like oxidized LDL
receptor-1 (LOX-1) on endothelial cells (Chen et al.,
2006) and CD36 on macrophages (Yamashita et al.,
2007). Upon receptor-mediated uptake of oxLDL into
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Figure 4. Schematic of effects of oxLDL binding to LOX-1.
LOX-1 on both vascular endothelial cells and dorsal root
ganglia neurons will bind oxLDL. Subsequently, the oxLDL
may be endocytosed or transcytosed. Receptor binding
initiates a signaling pathway leading to the activation of
NAD(P)H oxidase and may also alter mitochondrial generation
of reactive oxygen species. Glucose independently affects
these same cellular targets.
endothelial cells, oxLDL is transported through the
endothelial cell and extruded into the subendothelial
region within tissues (Li and Mehta, 2005). A schematic
showing the expression of LOX-1 and the potential
effects of oxLDL binding is shown in Fig. 4. LOX-1
expression is upregulated by oxLDL, which in turn
increases intracellular O .−2 production (Hu et al.,
2003). Shear stress, tumor necrosis factor-α, and
free radicals all increase LOX-1 expression levels
(Hu et al., 2003), while lipid lowering drugs decrease
expression (Draude et al., 1999). Hyperglycemia, AGE,
and C-reactive protein also increase LOX-1 expression
(Iwashima et al., 2000; Schalkwijk and Stehouwer,
2005; Rudijanto, 2007). Indeed, glucose stimulates
LOX-1 expression in both endothelial cells and
macrophages, prevented by antioxidants and inhibitors
of MAPK and NF-κB (Li et al., 2003; 2004; Dandapat
et al., 2007). LOX-1 is upregulated in renal tubules
in obese, diabetic rats and its activation leads to
inflammation and nephropathy (Ueno et al., 2003;
Dominguez et al., 2008; Kelly et al., 2008). Finally, LOX-
1 is also expressed on neurons, and polymorphisms in
the LOX-1 gene are associated with neurodegenerative
disease in humans (Papassotiropoulos et al., 2005).
We examined LOX-1 expression in DRG neurons, and
found basal expression that was further increased by
exposure to oxLDL (Vincent et al., 2009). Selected
data are presented in Fig. 5. Subsequent to LOX-
1 activation, the DRG neurons rapidly activated
NAD(P)H oxidase, increased superoxide generation,
and activated a programmed cell death mechanism.
DRG neuron injury in the presence of oxLDL was
prevented by a LOX-1 blocking antibody, the NAD(P)H
oxidase inhibitor apocyanin, or the antioxidant a-lipoic
acid (Vincent et al., 2009).
These data suggest that, in diabetes, neurons
are exposed to both glucose and oxLDL which
independently increase ROS, and glucose may
sensitize neurons to oxLDL-mediated damage via
upregulation of LOX-1. Interestingly, oxLDL decreases
native LDL-receptor expression in a LOX-1-dependent
manner (Hu et al., 2003). Given the critical role for
native LDL receptors in neuronal functioning, synapse
maintenance, and myelination following injury (Herz
and Bock, 2002), oxLDL could also predispose neurons
to glucose-mediated injury by decreasing native LDL
receptor. These ideas await further exploration.
Lipids and Diabetic Neuropathy
If the idea that dyslipidemia contributes to the
development of diabetic neuropathy is true (McManis
et al., 1994), lipid lowering drugs may be beneficial
in the treatment of diabetic neuropathy. Fenofibrate
is a PPARa agonist that lowers plasma lipids by
improving their removal by the liver and improving
fatty acid metabolism (Harano et al., 2006; Aasum
et al., 2008). In genetic dyslipidemia in mice, including
ApoE knockout, leptin deficient, and LDL receptor
knockout mice, fenofibrate improves the lipid profile
and increases high-density lipoprotein (Lie et al., 2005;
Kooistra et al., 2006; Srivastava et al., 2006). These
lipid improvements correlate with prevention of insulin
resistance and atherosclerosis (Calkin et al., 2007;
Xie et al., 2007; Aasum et al., 2008). Interest in this
drug treatment has expanded with the demonstration
that fenofibrate dramatically improves hyperglycemia,
insulin resistance, albuminuria, and glomerular lesions
in db/db mice (Park et al., 2006). The FIELD trial
demonstrated that fenofibrate improves signs and
progression of retinopathy and nephropathy (FIELD
Study, 2007; Keech et al., 2007; Simo and Hernandez,
2007; Davis et al., 2008; Firth, 2008). The Fremantle
Diabetes Study was an observational investigation
of 1,237 patients with type 2 diabetes. The data
suggest that therapy with a statin or fibrate protects
against diabetic peripheral sensory neuropathy, but
calls for confirmatory evidence via a randomized
clinical trial (Davis et al., 2008). Fenofibrate may also
provide neuroprotection against stroke (Deplanque
et al., 2003). We recently demonstrated the potent
ability of fenofibrate to prevent hyperglycemia-induced
DRG neuron injury in vitro by decreasing mitochondrial
262
































































































Figure 5. High glucose and oxLDL cause cell death in dorsal root ganglia (DRG) neurons via NAD(P)H oxidase. Adult DRG
neurons were exposed to high glucose (25.7 mM) or increasing concentrations of oxLDL and then cell death was quantitated
by caspase 3 activation after 5 h. DRG neurons were additionally pretreated with LOX-1 neutralizing antibody (Anti-LOX-1,
100 mg/ml), apocyanin (Apo, 1 mM), or a-lipoic acid (LA, 100 mM). n = 9, *p < 0.01 compared to untreated control, +p < 0.01
compared to no pretreatment (None). (B) Adult DRG neurons were exposed to 30 mg/ml oxLDL and then immunolabeled
for NAD(P)H oxidase subunits p47 or gp91. In (B), adult DRG neurons were exposed to high glucose (25.7 mM) or oxLDL
(30 mg/ml) for 1 h or 3 h, then lysed for biochemical assays of NAD(P)H oxidase. *p < 0.01 compared to untreated control,
+p < 0.05 compared to untreated control (reproduced from Vincent et al., 2009).
O .−2 generation (Vincent and Feldman, 2008). We
are following this study with an intervention in type
1 diabetic mice and have demonstrated that 0.1%
w/w fenofibrate chow significantly decreases total
cholesterol and LDL triglycerides (unpublished data).
Future Directions
We maintain our stand that hyperglycemia is also
a key mediator of DRG neuron injury particularly
in poorly controlled diabetes. Therefore, compounds
that improve glycemic control will assist in the
prevention of complications. Metformin, a biguanide
compound, improves insulin resistance by reducing
gluconeogenesis and enhancing peripheral glucose
uptake, promoting reduction of the plasma glucose
level (Yoon et al., 2007). Metformin remains as one
of the most used glucose regulating drugs in type
2 diabetes (Saenz et al., 2005) and is used in
preclinical trials in mice (Yoon et al., 2007; Algire
et al., 2008). Interestingly, dyslipidemia increases
in adolescent type 1 diabetic patients with poor
glycemic control, again highlighting the complex
interplay between glycemia and dyslipidemia (Shamir
et al., 2008). Taken together, the data indicate
that strategic use of NAD(P)H oxidase inhibition,
antioxidants, anti-LOX-1 therapy, anti-hyperglycemia,
and lipid lowering therapies will prevent diabetic
neuropathy. Each of these components has been
tested in rodents with positive results (Cotter and
Cameron, 2003; Park et al., 2006; Dominguez et al.,
2008). Individually, these strategies have not produced
significant results in clinical trials, with the exception of
a-lipoic acid (Ziegler et al., 2006). Current investigations
are focusing on metabolic deficits in the axon,
particularly at the mitochondria (Figueroa-Romero
et al., 2008; Wiggin et al., 2008; Edwards et al., 2009).
Further drug refinement and subcellular targeting may
be the key to improved efficacy against neuronal injury.
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